The applicant proposes first to evaluate the efficacy of a mutant form of the HIV receptor in blocking replication of HIV-1. This receptor, designated sCD4-KDEL, contains a specific retention signal for the endoplasmic reticulum and blocks transport of the HIV-1 envelope glycoprotein from the ER to the cell surface. Expression of this molecule at high levels in T-cells is likely to suppress assembly of infectious HIV-1. Ultimately, expression of this molecule might be useful in a procedure of intracellular immunization designed to prevent HIV maturation in a patient's T-cells. The second series of experiments proposed are closely related to the first. Here they would like to generate other mutant forms of CD4 containing specific signals that target the HIV glycoprotein for degradation in lysosomes or in the endoplasmic reticulum. Their third goal is to determine the effect of the HIV glycoprotein on the tyrosine protein kinase p561ck which is bound to the cytoplasmic domain of CD4 in T-cells. They are particularly interested in determining the effects on kinase activity and on the substrates phosphorylated. Because intracellular tyrosine protein kinases have been implicated in regulation of cell growth, regulation of p561ck could be relevant to the pathology of AIDS. The fourth goal is to develop a system in which the HIV-1 glycoprotein can be incorporated into the VSV particles in the absence of any HIV. These experiments will employ a virus rescue system recently developed in the laboratory. If infectious VSV particles containing altered gp12O/41 can be generated, they would have an immediate use in rapid tests for HIV neutralizing antibody which would not require growth of HIV. These pseudotypes would be safe to work with as they could not contain any HIV or HIV(VSV) pseudotypes and might prove useful as a vaccine if produced on a large scale.
|Roberts, A; Kretzschmar, E; Perkins, A S et al. (1998) Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 72:4704-11|
|Degar, S; Johnson, J E; Boritz, E et al. (1996) Replication of primary HIV-1 isolates is inhibited in PM1 cells expressing sCD4-KDEL. Virology 226:424-9|
|Buonocore, L; Turi, T G; Crise, B et al. (1994) Stimulation of heterologous protein degradation by the Vpu protein of HIV-1 requires the transmembrane and cytoplasmic domains of CD4. Virology 204:482-6|
|Owens, R J; Burke, C; Rose, J K (1994) Mutations in the membrane-spanning domain of the human immunodeficiency virus envelope glycoprotein that affect fusion activity. J Virol 68:570-4|
|Buonocore, L; Rose, J K (1993) Blockade of human immunodeficiency virus type 1 production in CD4+ T cells by an intracellular CD4 expressed under control of the viral long terminal repeat. Proc Natl Acad Sci U S A 90:2695-9|
|Owens, R J; Rose, J K (1993) Cytoplasmic domain requirement for incorporation of a foreign envelope protein into vesicular stomatitis virus. J Virol 67:360-5|
|Crise, B; Rose, J K (1992) Identification of palmitoylation sites on CD4, the human immunodeficiency virus receptor. J Biol Chem 267:13593-7|